Kezar Life Sciences Inc
kezarlifesciences.comKezar Life Sciences (NASDAQ: KZR) is a clinical-stage biopharmaceutical company that has developed small-molecule drug candidates targeting autoimmune diseases and cancer. The company has generated no product revenue since inception, with its only revenue to date consisting of collaboration payments, specifically an upfront payment under a license agreement with Everest Medicines II (HK) Limited. As of December 31, 2025, KZR had an accumulated deficit of $490.5 million, with net losses of $56.0 million, $83.7 million, and $101.9 million for the years ended December 31, 2025, 2024, and 2023, respectively. In 2025, the company reduced its workforce by approximately 70% and suspended various development efforts while evaluating strategic alternatives. In March 2026, it sold its Sec61-based discovery and development program assets to Enodia Therapeutics SAS, retaining its zetomipzomib program. The company is headquartered in South San Francisco, California.
Products & Services
Zetomipzomib, a small-molecule drug candidate licensed from Onyx under the Onyx License Agreement, for which KZR has paid $5.0 million in milestone payments to date and owes up to $167.5 million in additional milestone payments plus tiered royalties on net sales. The Sec61-based discovery and development program assets were sold to Enodia Therapeutics SAS in March 2026.
Revenue Model
Collaboration revenue from upfront, milestone, and contingent payments under licensing agreements, specifically the Everest Medicines II license agreement. No product revenue has been generated as of December 31, 2025. Future milestone payments from Everest are contingent on achieving predefined development objectives.
Customers & Markets
Licensing partner Everest Medicines II (HK) Limited is the sole revenue source to date. End markets are autoimmune diseases and oncology, with no approved products and no commercial customers as of the filing date.
Geographic Exposure
Headquartered in South San Francisco, California. Operations primarily in the United States. The Everest Medicines II license covers rights outside the United States, suggesting ex-U.S. geographic rights have been partially out-licensed.
Financial Snapshot
Loading...
